Collegium Pharma (COLL) Posts Q1 Loss of $0.29/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Collegium Reports First Quarter 2019 Financial Results
May 8, 2019 4:03 PM EDTXtampza® ER Net Product Revenues of $25.1 million in the First Quarter of 2019, a 59% increase over the First Quarter of 2018 and a 36% increase on a Consecutive-Quarter Basis
Net loss of $9.7 million in the First Quarter of 2019 compared to a net loss of $18.7 million in the First Quarter of 2018Conference call scheduled for today at 4:30 p.m. ET
STOUGHTON, Mass., May 08, 2019 (GLOBE NEWSWIRE) --... More
